2019
Clinical and economic burden of heparin-induced thrombocytopenia in hospitalized patients undergoing percutaneous peripheral arterial interventions
Subahi A, Osman M, Adegbala O, Abubakar H, Kheiri B, Yassin A, Khalid M, Akintoye E, Eljack A, Osman K, Alkhouli M. Clinical and economic burden of heparin-induced thrombocytopenia in hospitalized patients undergoing percutaneous peripheral arterial interventions. Vascular 2019, 28: 81-86. PMID: 31382836, DOI: 10.1177/1708538119868615.Peer-Reviewed Original ResearchConceptsVenous thrombosis/pulmonary embolismAcute kidney injuryKidney injuryIschemic strokePulmonary embolismHigh riskDeep venous thrombosis/pulmonary embolismPercutaneous peripheral arterial interventionsICD-9-CM codesHospital mortality differenceProlonged hospital stayHospital-level characteristicsPeripheral arterial interventionsNational Inpatient SampleHospital outcomesHospital stayIntervention patientsAbsence of heparinBaseline characteristicsHome dischargeLonger hospitalizationArterial interventionsHospitalized patientsInpatient SampleThrombocytopenia
2018
Angiogenesis in peripheral arterial disease
Inampudi C, Akintoye E, Ando T, Briasoulis A. Angiogenesis in peripheral arterial disease. Current Opinion In Pharmacology 2018, 39: 60-67. PMID: 29529399, DOI: 10.1016/j.coph.2018.02.011.Peer-Reviewed Original ResearchConceptsPeripheral arterial diseaseCritical limb ischemiaVascular endothelial growth factorHepatocyte growth factorFibroblast growth factorGrowth factorArterial diseaseTherapeutic angiogenesisCell therapyNew arterial vesselsAnkle-brachial indexPreferred therapeutic strategyPrevention of amputationProgenitor cell therapyAdipose-derived progenitor cellsEndothelial growth factorStem cell therapyAngiogenic growth factorsClaudication symptomsAdvanced diseaseAmputation rateLimb ischemiaInvestigational therapiesUlcer healingPeripheral arteries